Q2 FY27: Glenmark maintains guidance as core growth stays strong
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Glenmark reported Q2 FY27 revenue of Rs 42,473 million and H1 revenue of Rs 82,658 million. Like-for-like Q2 growth was about 20%, with India up about 14%, North America core business up 31% and Emerging Markets up 33.2%. Reported Q2 revenue fell 29.8% versus a prior-year out-licensing benefit. EBITDA was Rs 8,638 million at a 20.3% margin and adjusted profit was Rs 4,852 million at 11.4%. Management kept FY27 guidance.
Core growth and FY27 guidance support sentiment, while launches add potential. Near-term sales face a weak base due to prior-year licensing income.